Acurx Pharmaceuticals Announces Publication of Preclinical Data on Oral Pol IIIC Inhibitors

Article summary

Acurx Pharmaceuticals published preclinical data in ASM Spectrum demonstrating that its oral DNA polymerase IIIC inhibitors exhibit in vivo activity and microbiome-sparing effects compared to linezolid.